(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Signature Scents: A Manual for Outstanding Fragrances - 2France will build a new aircraft carrier as it increases defense spending
- 3The Most Compelling Innovation Advancements Somewhat recently
- 4US bishops officially ban gender-affirming care at Catholic hospitals
- 5The most effective method to Pick the Right Teeth Substitution Choice for You
- I’m a dad to an autistic child. Here’s how you can make the holidays easier for all of us.
- Do you lean your seat back on the plane? These travel pros — and real-life couple — won't do it.
- More people are addicted to marijuana, but fewer of them are seeking help, experts say
- Instructions to Amplify Certifiable Experience While Chasing after an Internet Advertising Degree
- 10 Famous Frozen yogurt Flavors All over The Planet
- Surveys of Music Collections by Film Stars
- The Best Web-based Courses for Expertise Improvement
- The Response to Self-improvement: Embracing a Development Outlook
- Support Your Body: A Manual for Smart dieting and Sustenance
